OCUPHIRE PHARMA INC (OCUP) Stock News

USA - NASDAQ:OCUP - US67577R1023 - Common Stock

1.17 USD

-0.16 (-12.03%)

Last: 10/23/2024, 8:00:03 PM

1.1601 USD

-0.01 (-0.85%)

After Hours: 10/23/2024, 8:00:03 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

OCUP Latest News, Press Relases and Analysis

All

Press Releases

a year ago - By: Foundation Fighting Blindness

The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics

a year ago - By: Benzinga

Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal

a year ago - By: Ademi LLP

Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders

a year ago - By: Ocuphire Pharma; Opus Genetics

Ocuphire Pharma Announces Acquisition of Opus Genetics

a year ago - By: Ocuphire Pharma

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology

a year ago - By: BusinessInsider

News Image

OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q2 2024

a year ago - By: Benzinga - Mentions: DUOT BSPK

Duos Technologies And 2 Other Stocks Under $3 Insiders Are Buying

a year ago - By: BusinessInsider

News Image

OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q1 2024

a year ago - By: Ocuphire Pharma

UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia

a year ago - By: InvestorPlace

OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q2 2024

a year ago - By: Ocuphire Pharma

Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update

a year ago - By: Ocuphire Pharma

Ocuphire Pharma to Present at Two Investor Conferences in August

a year ago - By: Ocuphire Pharma

Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July

2 years ago - By: BusinessInsider

News Image

OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023

a year ago - By: Ocuphire Pharma

Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy at Retina Meetings in June

a year ago - By: InvestorPlace

OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q1 2024

a year ago - By: Ocuphire Pharma

Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update

a year ago - By: Ocuphire Pharma

Ocuphire Pharma to Present at the Aegis Virtual Conference

a year ago - By: Ocuphire Pharma

First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery

1 years ago - By: Ocuphire Pharma

Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) by its Partner Viatris

2 years ago - By: InvestorPlace

OCUP Stock Earnings: Ocuphire Pharma Misses EPS, Misses Revenue for Q4 2023

2 years ago - By: Ocuphire Pharma

Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update

2 years ago - By: InvestorPlace - Mentions: INCY UTHR JAZZ VCYT ...

7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff

2 years ago - By: Ocuphire Pharma

Ocuphire Pharma to Present in the BIO CEO & Investor Conference

2 years ago - By: Ocuphire Pharma

Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 years ago - By: Seeking Alpha

Ocuphire Pharma appointed Nirav Jhaveri as CFO (NASDAQ:OCUP)

2 years ago - By: Ocuphire Pharma

Ocuphire Pharma Strengthens Leadership Team with Key Appointments

2 years ago - By: InvestorPlace - Mentions: BP HIMX

3 Value Stocks to Buy on the Dip: February 2024

2 years ago - By: Ocuphire Pharma

Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference

2 years ago - By: Ocuphire Pharma

Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 years ago - By: Seeking Alpha

Ocuphire Pharma files for a $175M mixed securities shelf (NASDAQ:OCUP)

2 years ago - By: Ocuphire Pharma

Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions

2 years ago - By: Ocuphire Pharma

Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII

2 years ago - By: InvestorPlace - Mentions: PSIX HEPS VTRS

Buy Alert: Analysts Say These 3 Growth Stocks Could Double in 2024

2 years ago - By: Ocuphire Pharma

Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2 years ago - By: Seeking Alpha

Ocuphire announces appointment of Joseph Schachle as chief operating officer (NASDAQ:OCUP)

2 years ago - By: Ocuphire Pharma

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer